Search

Displaying results 1961 - 1970 of 7498 in total
  1. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. … It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label].

  2. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.

  3. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … [A228423] Research into the action of hyoscyamine in published literature dates back to 1826.

    Mixtures: UR N-C Urinary Antiseptic
  4. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.

  5. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

  6. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.

  7. Drug

    Nandrolone phenpropionate

    go.drugbank.com/drugs/DB00984
    ApprovedIllicit

    It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.

  8. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  9. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.

    Synonyms: 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  10. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular